-
Views
-
Cite
Cite
Catrin E. Moore, John Paul, Dona Foster, Saeed A. Mahar, David Griffiths, Kyle Knox, Timothy E. Peto, A. Sarah Walker, Derrick W. Crook, Reduction of Invasive Pneumococcal Disease 3 Years After the Introduction of the 13-Valent Conjugate Vaccine in the Oxfordshire Region of England, The Journal of Infectious Diseases, Volume 210, Issue 7, 1 October 2014, Pages 1001–1011, https://doi.org/10.1093/infdis/jiu213
Close - Share Icon Share
Abstract
Background. The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease (IPD) is well described, but few reports exist on the additional impact of the 13-valent vaccine (PCV13).
Methods. We calculated the IPD incidence across all ages in a surveillance project following implementation of PCV7 (in September 2006) and PCV13 (in April 2010) in children aged <2 years (11 hospitals; 4935 cases).
Results. The overall incidence decreased from 10 cases/100 000 persons per year in 1996–1997 to 8 cases/100 000 persons per year in 2007–2008 and 7 cases/100 000 in 2012–2013. Declines were greater in children aged <2 years (from 37 cases/100 000 in 1996–1997 to 29 and 14 cases/100 000 in 2007–2008 and 2012–2013, respectively). The incidence of IPD due to PCV7 serotypes decreased in all ages after PCV7 introduction (P < .001), whereas the incidence of IPD due to the additional 6 serotypes in PCV13 and to nonvaccine types (NVTs) increased in children aged ≥2 years (P < .001 for both comparisons). The incidence of IPD due to the 6 additional serotypes in PCV13 declined significantly after PCV13 introduction in all ages (P ≤ .01), and the incidence of IPD due to NVTs declined significantly in children aged ≥2 years (P = .003). In 2011–2013, the overall incidences of IPD due to PCV7 serotypes, the 6 additional serotypes in PCV13, and NVTs were 0.3, 2.8, and 4.4 cases/100 000; the incidences among children aged <2 years were 0.9, 2.4, and 10.8 cases/100 000, respectively.
Conclusions. The annual incidence of IPD due to vaccine serotypes (1–3 cases/100 000) among children aged <2 years and nontarget groups demonstrates the success of PCV7 and PCV13. A substantially higher incidence of IPD due to NVTs indicates the importance of ongoing surveillance and extension of vaccine polyvalency.
